Skip to main content

Japan Approves Stem-Cell Treatments For Parkinson's, Heart Failure In World Firsts

3 days 12 hours ago
Long-time Slashdot reader fjo3 shared this report from Agence France-Presse: Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients within months. Pharmaceutical company Sumitomo Pharma said it received the green light for the manufacture and sale of Amchepry, its Parkinson's disease treatment that transplants stem cells into a patient's brain. Japan's health ministry also gave the go-ahead to ReHeart, heart muscle sheets developed by medical startup Cuorips that can help form new blood vessels and restore heart function, media reports said. The treatments could be on the market and rolled out to patients as early as this summer, reports said, citing the health ministry, becoming the world's first commercially available medical products using induced pluripotent stem cells... In a statement, Sumitomo Pharma said it had obtained "conditional and time-limited approval" for the manufacture and marketing of Amchepry under a system which is reportedly designed to get these products to patients as quickly as possible. The approval is a kind of "provisional license", the Asahi newspaper said, after the safety and efficacy of the treatment was judged based on data from fewer patients than in ordinary clinical trials for drugs. A trial led by Kyoto University researchers indicated that the company's treatment was safe and successful in improving symptoms. The study involved seven Parkinson's patients aged between 50 and 69, with each receiving a total of either five million or 10 million cells implanted on both sides of the brain... The patients were monitored for two years and no major adverse effects were found, the study said. Four patients showed improvements in symptoms. The article notes that "Worldwide, about 10 million people have the illness, according to the Parkinson's Foundation," while also notes that today's current therapies "improve symptoms without slowing or halting the disease progression..."

Read more of this story at Slashdot.

EditorDavid

OpenAI's Head of Robotics Resigns, Says Pentagon Deal Was 'Rushed Without the Guardrails Defined'

3 days 13 hours ago
In a tweet that's been viewed 1.3 million times in the last six hours, OpenAI's head of robotics announced their resignation. They said they "care deeply about the Robotics team and the work we built together," so this "wasn't an easy call," but offered this reason for resigning: AI has an important role in national security. But surveillance of Americans without judicial oversight and lethal autonomy without human authorization are lines that deserved more deliberation than they got. This was about principle, not people. I have deep respect for Sam and the team, and I'm proud of what we built together. "To be clear, my issue is that the announcement was rushed without the guardrails defined," explains a later tweet. "It's a governance concern first and foremost. These are too important for deals or announcements to be rushed." And when asked how many OpenAI employees had left after OpenAI signed their new Pentagon deal, the roboticist said... "I can't share any internal details." The roboticist previously worked at Meta before leaving to join OpenAI in late 2024, reports Engadget: OpenAI confirmed Kalinowski's resignation and said in a statement to Engadget that the company understands people have "strong views" about these issues and will continue to engage in discussions with relevant parties. The company also explained in the statement that it doesn't support the issues that Kalinowski brought up. "We believe our agreement with the Pentagon creates a workable path for responsible national security uses of AI while making clear our red lines: no domestic surveillance and no autonomous weapons," the OpenAI statement read.

Read more of this story at Slashdot.

EditorDavid